Rein Therapeutics Inc. (NASDAQ:RNTX) Stock Has Average Target Price of $6.00 According to Brokerages

Shares of Rein Therapeutics Inc. (NASDAQ:RNTX) have been assigned a consensus rating of “Hold” from the four analysts that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $6.00.

A number of analysts recently weighed in on the stock. HC Wainwright reiterated a “buy” rating on shares of Rein Therapeutics in a research note on Tuesday, August 18th. Maxim Group began coverage on Rein Therapeutics in a research report on Monday, July 20th. They set a “buy” rating and a $4.00 target price on the stock. Finally, Weiss Ratings cut shares of Rein Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, August 21st.

Rein Therapeutics Trading Up 20.7%

Shares of NASDAQ RNTX opened at $0.70 on Wednesday. The stock has a market cap of $60.75 million, a P/E ratio of -0.41 and a beta of 1.35. Rein Therapeutics has a twelve month low of $0.54 and a twelve month high of $2.18. The stock has a 50 day moving average of $0.75 and a two-hundred day moving average of $1.05.

Rein Therapeutics (NASDAQ:RNTX) last announced its earnings results on Friday, August 14th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.17. As a group, research analysts predict that Rein Therapeutics will post -0.47 earnings per share for the current year.

Institutional Trading of Rein Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Chicago Partners Investment Group LLC lifted its holdings in shares of Rein Therapeutics by 32.2% during the 1st quarter. Chicago Partners Investment Group LLC now owns 41,048 shares of the company’s stock valued at $53,000 after acquiring an additional 10,000 shares in the last quarter. Sequoia Financial Advisors LLC acquired a new stake in Rein Therapeutics during the second quarter worth about $260,000. Sigma Planning Corp boosted its holdings in shares of Rein Therapeutics by 41.0% during the first quarter. Sigma Planning Corp now owns 348,677 shares of the company’s stock valued at $453,000 after acquiring an additional 101,400 shares during the period. Finally, Velan Capital Investment Management LP bought a new position in Rein Therapeutics in the 2nd quarter worth approximately $1,768,000. 90.89% of the stock is currently owned by institutional investors and hedge funds.

Rein Therapeutics Company Profile

Rein Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for serious pulmonary and fibrotic diseases. The company’s research is centered on therapies intended to address the underlying biological mechanisms that drive tissue scarring and chronic disease progression.

Its lead investigational product is bexotegrast, an oral small-molecule inhibitor of the integrins αvβ1 and αvβ6. Rein Therapeutics is evaluating bexotegrast in clinical development for conditions including idiopathic pulmonary fibrosis, a progressive lung disease, and primary sclerosing cholangitis, a chronic disease that affects the bile ducts and can lead to liver damage.